Your browser doesn't support javascript.
loading
Pre-clinical validation study of a miniaturized electrochemical immunoassay based on square wave voltammetry for early detection of carcinoembryonic antigen in human serum.
Martínez-Mancera, Flavio Dolores; García-López, Patricia; Hernández-López, José Luis.
Afiliação
  • Martínez-Mancera FD; Centro de Investigación y Desarrollo Tecnológico en Electroquímica, S.C., Parque Tecnológico Querétaro S/N, P.O. Box 064, Pedro Escobedo, Querétaro C.P. 76703, Mexico.
  • García-López P; Instituto Nacional de Cancerología, Av. San Fernando No. 22, Col. Sección XVI, Del. Tlalpan, México, D.F., C.P. 14080, Mexico.
  • Hernández-López JL; Centro de Investigación y Desarrollo Tecnológico en Electroquímica, S.C., Parque Tecnológico Querétaro S/N, P.O. Box 064, Pedro Escobedo, Querétaro C.P. 76703, Mexico. Electronic address: jhernandez@cideteq.mx.
Clin Chim Acta ; 444: 199-205, 2015 Apr 15.
Article em En | MEDLINE | ID: mdl-25689793
BACKGROUND: The ELISA format for measuring carcinoembryonic antigen (CEA) serves as a reference standard against which other assays are compared. Because the World Health Organization (WHO) increasingly recommends the use of serum CEA as a diagnostic tool for cancer, it is relevant to explore the reliability of the new decentralized CEA point-of-care-testing (POCT) technologies that are available to physicians and patients, in compliance with mandates of the clinical laboratories' regulatory agencies. METHODS: Electrochemical immunoassay (ECIA) based on trace lead (Pb) analysis by anodic stripping techniques using sandwich-type immunocomplex conjugates: (MB)Ab/AgCEA/Ab(PbS), and a commercial ELISA test system with optical transmission. RESULTS: The ECIA provides better analytical performance than does the ELISA. The within assay precision coefficient of variance (%CVw) of the ECIA is lower than the value recommended by the Hong Kong Association of Medical Laboratories (HKAML), and the recoveries of CEA at 1.0, 5.0, 10.0, 25.0 and 50.0 ng/ml are in the range of 99-110% for control serum samples. The ECIA showed a minimal positive bias of 0.0267 ± 0.3270 ng/ml (P=0.9389). CONCLUSIONS: The proposed CEA screening technology can be practically employed for decentralized clinical analysis of CEA in human serum. Therefore, it can be viewed as a control method for personalized therapy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaio de Imunoadsorção Enzimática / Antígeno Carcinoembrionário / Biomarcadores Tumorais / Técnicas Eletroquímicas Tipo de estudo: Diagnostic_studies / Screening_studies Limite: Humans Idioma: En Revista: Clin Chim Acta Ano de publicação: 2015 Tipo de documento: Article País de afiliação: México País de publicação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaio de Imunoadsorção Enzimática / Antígeno Carcinoembrionário / Biomarcadores Tumorais / Técnicas Eletroquímicas Tipo de estudo: Diagnostic_studies / Screening_studies Limite: Humans Idioma: En Revista: Clin Chim Acta Ano de publicação: 2015 Tipo de documento: Article País de afiliação: México País de publicação: Holanda